CXCL13 and B-cell chronic lymphocytic leukemia: For instance, ibrutinib treatment inhibited CXCL13 secretion, reduced CLL cell recruitment, and disaggregated CLL cell–macrophage interactions in the bone marrow microenvironment [119].